INDICATION AND LIMITATION OF USE

Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

This site is intended for US healthcare professionals only.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

  • CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Full Safety Information Below

Vyvanse is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

IMPORTANT SAFETY INFORMATION    This site is intended for US healthcare professionals only.

WARNING: ABUSE AND DEPENDENCE

  • | CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Full Safety Information Below

Vyvanse (lisdexamfetamine dimesylate) is a once-daily treatment for ADHD.¹

Prodrug Formulation

Lisdexamfetamine, a prodrug of dextroamphetamine, is rapidly absorbed from the gastrointestinal (GI) tract and converted to dextroamphetamine primarily in the blood.1,2

The clinical relevance of the prodrug formulation has not been established. In general, prodrugs are pharmacologically inert chemical derivatives that are converted in vivo into active drug molecules.³

GI Tract

After oral administration, lisdexamfetamine is rapidly absorbed from the GI tract.²

In Circulation

Lisdexamfetamine is converted to dextroamphetamine and l-lysine primarily in the blood. This occurs due to the hydrolytic activity of red blood cells.¹

The conversion of lisdexamfetamine in the blood produces dextroamphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulant activity.¹

In CNS

Amphetamines block the reuptake of catecholamines norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.¹

The parent drug, lisdexamfetamine, does not bind to the sites responsible for the reuptake of norepinephrine and dopamine in vitro.¹

The clinical significance of in vitro data is unknown. The mode of therapeutic action in ADHD is not known.¹

You are about to leave vyvansepro.com.

Please be advised that Shire has no control over the content or presentation of the site you are about to view.

Cancel Continue